Phase II Trial of Y90 Ibritumomab Tiuxetan Post Rituximab-Cyclophosphamide, Doxorubicn, Vincristine and Prednisone Chemotherapy for Newly Diagnosed Patients With Advanced Stage Follicular Lymphoma

Trial Profile

Phase II Trial of Y90 Ibritumomab Tiuxetan Post Rituximab-Cyclophosphamide, Doxorubicn, Vincristine and Prednisone Chemotherapy for Newly Diagnosed Patients With Advanced Stage Follicular Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms ZEVISS
  • Most Recent Events

    • 15 Jun 2016 Status changed from recruiting to completed.
    • 07 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top